TherapeuticsMD (TXMD) Reports In-Line Q2 EPS

TherapeuticsMD (NASDAQ: TXMD) reported Q2 EPS of ($0.11), in-line with the analyst estimate of ($0.11). Revenue for the quarter came in at $23 million versus the consensus estimate of $22.11 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• JPMorgan Downgrades HCL Technologies (HCLT:IN) to Underweight
• BMO Capital Upgrades CES Energy Solutions Corp. (CEU:CN) (CESDF) to Outperform